1. Home
  2. IH vs KPTI Comparison

IH vs KPTI Comparison

Compare IH & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iHuman Inc.

IH

iHuman Inc.

N/A

Current Price

$2.20

Market Cap

116.0M

Sector

Real Estate

ML Signal

N/A

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

N/A

Current Price

$6.01

Market Cap

94.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IH
KPTI
Founded
1996
2008
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.0M
94.6M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
IH
KPTI
Price
$2.20
$6.01
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
11.2K
177.9K
Earning Date
12-19-2025
11-03-2025
Dividend Yield
3.83%
N/A
EPS Growth
N/A
N/A
EPS
0.29
N/A
Revenue
$123,215,612.00
$142,530,000.00
Revenue This Year
$39.02
$3.82
Revenue Next Year
N/A
$3.18
P/E Ratio
$7.76
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.55
$3.51
52 Week High
$3.60
$12.45

Technical Indicators

Market Signals
Indicator
IH
KPTI
Relative Strength Index (RSI) 33.83 54.33
Support Level $2.15 $5.99
Resistance Level $2.40 $7.48
Average True Range (ATR) 0.16 0.50
MACD -0.04 0.04
Stochastic Oscillator 12.99 48.62

Price Performance

Historical Comparison
IH
KPTI

About IH iHuman Inc.

iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: